A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines

A global regulatory science agenda for vaccines

(2013) Lindsay Elmgren et al.   VACCINE

Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research

(2012) Stuart M. Levitz et al.   CELL

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

Aflunov®: a prepandemic influenza vaccine

(2012) Roberto Gasparini et al.   Expert Review of Vaccines

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy

(2012) Christopher B. Fox et al.   Influenza and Other Respiratory Viruses

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

(2012) E. Caproni et al.   JOURNAL OF IMMUNOLOGY

Advancing Prediction of Tissue Distribution and Volume of Distribution of Highly Lipophilic Compounds from a Simplified Tissue-Composition-Based Model as a Mechanistic Animal Alternative Method

(2012) Patrick Poulin et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Overview of global regulatory toxicology requirements for vaccines and adjuvants

(2012) Yuansheng Sun et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

(2011) Adriano Arguedas et al.   Human vaccines & immunotherapeutics

Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles

(2011) Emidio E. Pistilli et al.   JOURNAL OF CLINICAL INVESTIGATION

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

(2011) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Immunological mechanisms of vaccination

(2011) Bali Pulendran et al.   NATURE IMMUNOLOGY

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions

(2011) Christopher B. Fox et al.   VACCINE

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

(2010) Hana El Sahly   Expert Review of Vaccines

Reverse Vaccinology: Developing Vaccines in the Era of Genomics

(2010) Alessandro Sette et al.   IMMUNITY

Safety Review: Squalene and Thimerosal in Vaccines

(2010) Marc Montana et al.   THERAPIE

Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation

(2009) Lucie Kalvodova   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Quantitative Analysis of the Deltoid and Rotator Cuff Muscles in Humans and Great Apes

(2009) J. M. Potau et al.   INTERNATIONAL JOURNAL OF PRIMATOLOGY

Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

(2009) Shweta R. Urva et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Squalene Emulsions for Parenteral Vaccine and Drug Delivery

(2009) Christopher Fox   MOLECULES

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE